OncoMatch/Clinical Trials/NCT04744116
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Is NCT04744116 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Ruxolitinib for hematopoietic and lymphoid cell neoplasm.
Treatment: Ruxolitinib — This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients with acute graft versus host disease that does not respond to steroid therapy (steroid-refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. cb-MSCs are a type of tissue helper cell that can be removed from donated umbilical cord blood tissue and grown into many different cell types that can be used to treat cancer and other disease, such as graft versus host disease. This trial aims to learn if adding cb-MSCs to ruxolitinib may help control steroid-refractory acute graft versus host disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Disease stage
Required: Stage II, III, IV
Prior therapy
Must have received: systemic corticosteroid (methylprednisolone) — acute GVHD
No improvement after treatment with methylprednisolone at ≥ 2.0 mg/kg/day or equivalent for minimum 7 days, or progressive symptoms after minimum 3 days, or a flare in acute GVHD while on systemic steroids
Cannot have received: secondary systemic therapy for acute GVHD (ruxolitinib >96 hours before initiation of therapy) (ruxolitinib)
Secondary systemic therapy for acute GVHD ruxolitinib greater than 96 hours before initiation of therapy
Cannot have received: primary treatment with agents other than alpha-1 antitrypsin (AAT), glucocorticoids, and ruxolitinib
Primary treatment with agents other than alpha-1 antitrypsin (AAT) glucocorticoids and ruxolitinib
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify